Sotagliflozin Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Sotagliflozin Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
67
Registered trials
67
Result records
2
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Sotagliflozin can convert its Small molecule drug profile and SGLT1 x SGLT2 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Sotagliflozin (query alias: sotagliflozin) |
|---|---|
| Modality / target | Small molecule drug; SGLT1 x SGLT2; SGLT1 inhibitors, SGLT2 inhibitors |
| Highest global status | Approved |
| Originator | NCI Healthcare LLC |
| Active developers | Viatris, Inc., Lexicon Pharmaceuticals, Inc., BGP Pharma ULC |
The MCP disease footprint includes Heart Failure, Diabetes Mellitus, Type 1, Diabetic Nephropathies. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07547878 | Phase 4 | Not yet recruiting | 64 | On-study retention rate at 6 months |
| NCT07421518 | Phase 2 | Not yet recruiting | 75 | Ketone events with Beta-hydroxybutyrate (BOHB) >1.5 mmol/L |
| NCT07572175 | Phase 2 | Not yet recruiting | 60 | Left Ventricular Ejection Fraction (LVEF) by Cardiac MRI |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
SOTA-P-CARDIA Trial: A Randomized Trial of Sotagliflozin in HFpEF Patients Without Diabetes
Phase 4; n=88; evaluation: not stated. Reported fields: Changes in Left Ventricular Mass in CMRI(Mean) = 5.7 grams (95% Confidence Interval, 2.1 - 9.2); Changes in Left Ventricular Mass in CMRI(Mean) = -8.6 grams (95% Confidence Interval, -11.9 to -5.3); -
Cardiovascular Risk Prediction Modelling with Sotagliflozin in Type 1 Diabetes: Analysis of inTandem 1-3 Trials
Not Applicable; n=2829; evaluation: Positive. Reported fields: CVD risk(estimated 10-year risk, relative change fr baseline) = Sotagliflozin significantly reduced the estimated 10-year CVD risk following 24 weeks of treatment compared with placebo. ; CVD risk(estimated 10-year risk, relative change fr baseline) = Sotagliflozin significantly reduced the estimated 10-year CVD risk following 24 weeks of treatment compared with placebo.
Efficacy of sotagliflozin among older adults: a pooled analysis of SCORED and SOLOIST-WHF
Phase 3; n=11806; evaluation: Positive. Reported fields: Composite endpoint = 8.9 event/100 patient-year ; Composite endpoint = 10.2 event/100 patient-year ; Composite endpoint = 12.4 event/100 patient-year
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Sotagliflozin addresses Heart Failure, Diabetes Mellitus, Type 1, Diabetic Nephropathies. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 2 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2024-10-16 | Lexicon Announces Exclusive Licensing Agreement With Viatris for Sotagliflozin in All Markets Outside of the U.S. and Europe | Approved | US$25.0M upfront |
| 2019-09-09 | Lexicon Pharmaceuticals Announces Termination of Alliance and Settlement with Sanofi | Phase 3 | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “New application of compound Sotagliflozin for resisting foot and mouth disease virus”. The milestone feed surfaced a patent-application signal described as “Amorphous obicetrapib and SGLT2 inhibitor combination”. The milestone feed surfaced a patent-application signal described as “Combination formulation comprising sacubitril-valsartan and SGLT-2 inhibitor having improved stability and dissolution rate”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
